To prepare the subject pharmaceutical preparation capable of effective ly preventing cell adhesion by EDA associated with a disease such as fibrosis by using a material for inhibiting bond of αvβ5 integrin to fibronectin EDA caused in the presence of serum as an active ingredient.
This pharmaceutical preparation contains a material for inhibiting the bond of αvβ 5 integrin to fibronectin EDA caused in the presence of serum as an active ingredient. Preferably, the pharmaceutical preparation contains a material for inhibiting the bond of the αvβ5 integrin to the fibronectin EDA and vironectin of a component in the serum as an active ingredient. The inhibiting material preferably has its inhibitory activity larger than that of GRGDSP peptide. For example, an anti-EDA antibody, an anti-αvβ5 integrin antibody, etc., are cited. The daily dose of the objective pharmaceutical preparation is ordinary 0.1-50 mg per adult in the case of oral administration.
YASUNAGA KUNIO
KOBAYASHI SEIJI
